XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | ---- | ---- | -59.12%506.95M | ---- | ---- | ---- | 93.15%1.24B | ---- | ---- |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | ---- | ---- | -6.39%-55.64M | ---- | ---- | ---- | -83.69%-52.3M | ---- | ---- |
Attributable subsidiary (profit) loss | ---- | ---- | ---- | 14.05%3.07M | ---- | ---- | ---- | 531.69%2.69M | ---- | ---- |
Impairment and provisions: | ---- | ---- | ---- | 383.80%41.55M | ---- | ---- | ---- | -90.44%8.59M | ---- | ---- |
-Impairmen of inventory (reversal) | ---- | ---- | ---- | 1,018.62%31.23M | ---- | ---- | ---- | --2.79M | ---- | ---- |
-Other impairments and provisions | ---- | ---- | ---- | 78.06%10.32M | ---- | ---- | ---- | --5.8M | ---- | ---- |
Revaluation surplus: | ---- | ---- | ---- | 163.77%232.95M | ---- | ---- | ---- | -108.49%-365.28M | ---- | ---- |
-Other fair value changes | ---- | ---- | ---- | 163.77%232.95M | ---- | ---- | ---- | -108.49%-365.28M | ---- | ---- |
Asset sale loss (gain): | ---- | ---- | ---- | -39.08%251K | ---- | ---- | ---- | 0.98%412K | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | -39.08%251K | ---- | ---- | ---- | 0.98%412K | ---- | ---- |
Depreciation and amortization: | ---- | ---- | ---- | 9.57%142.13M | ---- | ---- | ---- | --129.72M | ---- | ---- |
-Amortization of intangible assets | ---- | ---- | ---- | -41.95%9.06M | ---- | ---- | ---- | --15.61M | ---- | ---- |
Financial expense | ---- | ---- | ---- | -12.28%3.14M | ---- | ---- | ---- | -9.59%3.58M | ---- | ---- |
Exchange Loss (gain) | ---- | ---- | ---- | 55.79%-12.11M | ---- | ---- | ---- | -145.42%-27.4M | ---- | ---- |
Special items | ---- | ---- | ---- | 226.14%6.03M | ---- | ---- | ---- | -113.60%-4.78M | ---- | ---- |
Operating profit before the change of operating capital | ---- | ---- | ---- | -7.16%868.32M | ---- | ---- | ---- | 48.81%935.24M | ---- | ---- |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | ---- | ---- | 165.57%158.67M | ---- | ---- | ---- | -1,483.48%-241.99M | ---- | ---- |
Accounts receivable (increase)decrease | ---- | ---- | ---- | 88.55%-11.71M | ---- | ---- | ---- | -252.58%-102.25M | ---- | ---- |
Accounts payable increase (decrease) | ---- | ---- | ---- | -172.21%-89.35M | ---- | ---- | ---- | 488.12%123.74M | ---- | ---- |
prepayments (increase)decrease | ---- | ---- | ---- | -1,121.13%-83.41M | ---- | ---- | ---- | 261.14%8.17M | ---- | ---- |
Special items for working capital changes | ---- | ---- | ---- | -119.58%-67.77M | ---- | ---- | ---- | 174.57%346.07M | ---- | ---- |
Cash from business operations | ---- | -31.81%229.49M | ---- | -27.52%774.75M | ---- | -42.94%336.54M | ---- | 47.20%1.07B | ---- | 156.45%589.75M |
Other taxs | ---- | 19.12%-73.22M | ---- | -23.61%-152.72M | ---- | -104.56%-90.53M | ---- | -197.43%-123.55M | ---- | -60.92%-44.26M |
Adjustment items of business operations | -57.11%192.33M | ---- | 977.61%119.95M | ---- | -42.38%448.44M | ---- | -118.25%-13.67M | ---- | 67.93%778.29M | ---- |
Net cash from operations | -57.11%192.33M | -36.48%156.28M | 977.61%119.95M | -34.21%622.03M | -42.38%448.44M | -54.90%246.01M | -118.25%-13.67M | 38.09%945.43M | 67.93%778.29M | 169.43%545.49M |
Cash flow from investment activities | ||||||||||
Dividend received - investment | 741.85%190.46M | ---- | 470.08%11.48M | --1.3M | 25.45%22.62M | ---- | -55.30%2.01M | ---- | 21.22%18.03M | ---- |
Decrease in deposits (increase) | ---- | 35,369.42%1.57B | ---- | 37.41%-21.8M | ---- | --4.42M | ---- | 97.47%-34.82M | ---- | ---- |
Sale of fixed assets | 448.23%555.93K | 1,138.64%545K | -28.99%3.35K | 38.89%150K | 270.31%101.41K | 340.00%44K | 148.29%4.72K | -56.28%108K | -84.73%27.38K | -94.35%10K |
Purchase of fixed assets | -25.64%-188.02M | -27.09%-128.35M | -5.61%-59.02M | 30.50%-186.78M | 31.43%-149.65M | 12.44%-100.99M | 22.36%-55.88M | -21.96%-268.75M | -62.23%-218.25M | -79.47%-115.34M |
Purchase of intangible assets | ---- | 45.10%-1.68M | ---- | 2.40%-5.95M | ---- | -104.68%-3.06M | ---- | 63.94%-6.09M | ---- | 90.16%-1.5M |
Sale of subsidiaries | ---- | --35M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Acquisition of subsidiaries | ---- | ---- | ---- | 95.51%-90.06M | 94.67%-90.06M | 88.04%-90.06M | ---- | ---2.01B | ---1.69B | ---753.18M |
Recovery of cash from investments | 360.20%2.31B | -3.78%308.9M | -56.09%90.77M | -33.32%605.05M | -34.87%501.5M | -47.90%321.04M | -37.35%206.72M | 14.96%907.4M | 97.94%770M | 94.63%616.17M |
Cash on investment | -667.50%-3.27B | -1,345.79%-2.53B | -100.00%-120M | 17.85%-617.35M | 52.58%-426.08M | 74.54%-175M | 68.42%-60M | 39.65%-751.5M | 58.34%-898.43M | 61.75%-687.43M |
Other items in the investment business | 108.25%9.2M | 196.00%4.44M | -32.44%9.2M | -96.68%850K | 132.60%4.42M | --1.5M | --13.62M | 2,464.00%25.64M | ---13.55M | ---- |
Net cash from investment operations | -592.72%-950.05M | -1,667.48%-744.23M | -163.45%-67.56M | 85.26%-314.58M | 93.25%-137.15M | 95.53%-42.11M | 46.85%106.48M | -3.18%-2.13B | -7.65%-2.03B | 39.67%-941.25M |
Net cash before financing | -343.41%-757.73M | -388.35%-587.96M | -43.55%52.39M | 125.86%307.45M | 124.85%311.29M | 151.52%203.9M | -37.04%92.81M | 14.09%-1.19B | 11.98%-1.25B | 70.85%-395.76M |
Cash flow from financing activities | ||||||||||
New borrowing | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --55.45M | --19.17M | ---- |
Refund | ---- | ---- | ---- | 88.29%-6.9M | 66.54%-6.87M | -300.47%-6.82M | 3.64%-861.7K | -1,481.39%-58.88M | -668.04%-20.54M | -12.72%-1.7M |
Issuing shares | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -98.37%88.54M | ---- | -99.38%32.74M |
Interest paid - financing | ---- | 30.08%-179K | ---- | -25.48%-2.64M | ---- | 16.34%-256K | ---- | -52.02%-2.1M | ---- | 4.38%-306K |
Dividends paid - financing | 44.18%-119.63M | ---- | ---- | -55.97%-214.24M | -55.72%-214.33M | ---- | 30.63%-55.07K | -44.82%-137.36M | -44.60%-137.63M | ---- |
Absorb investment income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -98.52%80.07M | ---- |
Other items of the financing business | -15.26%-129.19M | -27.30%-92.93M | -58.46%-37.93M | -439.43%-113.58M | -308.34%-112.09M | -98,548.65%-73M | -453.68%-23.94M | -3,114.66%-21.06M | 11.79%-27.45M | ---74K |
Net cash from financing operations | 25.34%-248.83M | -14.58%-107.25M | -52.61%-37.93M | -264.11%-361.68M | -285.81%-333.29M | -597.97%-93.6M | -197.61%-24.85M | -101.88%-99.33M | -101.64%-86.39M | -99.65%18.8M |
Effect of rate | -150.50%-6.97M | -101.39%-247K | 55.43%-2.8M | -77.56%8.41M | -68.11%13.8M | -25.37%17.78M | -95.26%-6.27M | 161.53%37.47M | 190.25%43.29M | 147.39%23.82M |
Net Cash | -4,475.92%-1.01B | -730.29%-695.21M | -78.72%14.46M | 95.79%-54.23M | 98.36%-22M | 129.26%110.3M | -60.69%67.96M | -132.98%-1.29B | -134.74%-1.34B | -109.56%-376.96M |
Begining period cash | -1.58%2.85B | -1.58%2.85B | -1.58%2.85B | -30.14%2.9B | -30.14%2.9B | -30.14%2.9B | -30.14%2.9B | 1,260.59%4.15B | 1,260.59%4.15B | 1,260.59%4.15B |
Cash at the end | -36.36%1.84B | -28.71%2.16B | -3.24%2.87B | -1.58%2.85B | 1.29%2.89B | -20.27%3.03B | -31.46%2.96B | -30.14%2.9B | -30.59%2.85B | -9.58%3.8B |
Cash balance analysis | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | KPMG | -- | -- | -- | KPMG | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.